Donate

Malecare Adds A New Teleconference About Immunotherapy and Advanced Prostate Cancer

Malecare announces the addition of our latest and informative teleconference about Immunotherapy and Advanced Prostate Cancer.  Joining me in the conference is Dr. Nicholas J. Vogelzang, M.D., a medical oncologist with the Comprehensive Cancer Centers of Nevada (CCCN) and serves as chair and site research leader, and as medical director of the Developmental Therapeutics Committee and Member [...]

A Correction of A Prior Post – How About Entering the Prostvac-VF Trail and Then Have Provenge?

On March 4th I wrote a post which included a suggestion that combining Provenge and the clinical trial of Prostvac-VF might provide an interesting one-two punch against advanced prostate cancer.  In the post I suggested that it could be interesting to have Provenge and then move immediately on to Prostvac. This was an error, I [...]

Markers for Predicting Clinical Responses to Sipuleucel-T (Provenge) in Castrate Resistant Prostate Cancer

Sipuleucel-T (Provenge) has shown in clinical trials that it prolongs overall survival (OS) in asymptomatic or minimally symptomatic men with castrate resistant prostate cancer (CRPC). Unlike many other treatments for men with CRPC there are not any reliable biomarkers to show that it is working for any individual.  There is also a lack of markers [...]

Castrate Resistant Prostate Cancer- What To Do Next?

Confusion, confusion and more confusion, that is how I would describe the current decision making process for a man with prostate cancer that has become newly castrate resistant. Just a few years ago the decision tree was clear, castrate resistant, immediately on to chemotherapy with docetaxel. Today, in this treatment space, we have a number [...]

Xtandi Shows Activity in Men with Prostate Cancer Resistant to Chemotherapy and Zytiga

Since its FDA approval in 2011 FDA abiraterone (Zytiga) has supplanted docetaxel (chemotherapy), other than perhaps Provenge, as preferred first-line treatment for metastatic castrate-resistant prostate cancer. August 2012 saw the FDA approval of enzalutamide (Xtandi) for the treatment of castrate-resistant prostate cancer after chemotherapy. Researchers performed a retrospective chart review at a large medical oncology [...]

An Important Follow-Up For Men Who Have Had Provenge

My blog post last Friday was among the top twenty most important ones I have written. I want to be sure that if you have taken Provenge commercially, meaning not during a clinical trial, you need to know that you might have been under-dosed and might need to be retreated. Dendreon, the company that manufactures [...]

Bulletin – Some Doses of Provenge That Were Given To Men Did Not Meet Quality Control Standards

It was announced that some dosages Provenge (sipuleucel-T) did not meet the potency release specification for CD54 upregulation, an error that might affect the ability of Provenge to kick-start the immune system. This quality control error affected less than 0.3% of Provenge’s commercial doses released since its commercial launch. Dendreon has agreed with the Food [...]

Positive Results for Xtandi in the Pre-Chemotherapy Space

It was announced today that after observing significant benefits in overall survival (OS) and radiographic progression free survival (PFS) ,the two co-primary endpoints of the the Xtandi pre-chemotherapy trial,  the Independent Data Monitoring Committee (IDMC) for The Phase 3 PREVAIL trial of enzalutamide in metastatic prostate cancer recommends that "the study be stopped and patients [...]

Step Therapy – The Creeping Crud Infecting Our Care Takes Another Bite Out Of Our Treatment  

Step therapy (ST) has again reared its most ugly head in our prostate cancer world, to the detriment of us, prostate cancer survivors and only to the benefit of private insurance payers. So, what is this “creeping crud,” Step Therapy (aka as Fail First Therapy)? Simply, ST is when insurance companies decide, without sound medical [...]

Great Video Worth Spending the 9 Minutes Required Discussing Provenge and the Use of Zytiga (Along with Prednisone)

OncLive Peer Exchange has put out a video about the issues that most concern many of us surrounding the use of Provenge (Sipuleucel-T).   The video is a 9 minute discussion with Drs. Raoul Concepcion (moderator), Leonard Gomella, Lawrence Karsh, Evan Yu and Mark Scholtz.  They examine the concern that so many men with advanced prostate [...]

Go to Top